RBC
NTLA icon

Romano Brothers & Co’s Intellia Therapeutics NTLA Stock Holding History

Romano Brothers & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-166
Closed -$5.79K – 735
2022
Q4 		$5.79K Buy
+166
New +$7.89K ﹤0.01% 817

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Romano Brothers & Co's NTLA Position: Q1 2023 in Review

Romano Brothers & Co sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 166 shares — an estimated $5.79K sold.

Romano Brothers & Co first reported a position in NTLA in Q4 2022 and held it in 1 quarter. The position peaked at $5.79K in Q4 2022. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • Romano Brothers & Co reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 166 Intellia Therapeutics shares in Q1 2023, an estimated $5.79K.
  • Romano Brothers & Co first reported a position in Intellia Therapeutics in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Intellia Therapeutics position peaked at $5.79K in Q4 2022.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.